Literature DB >> 3127127

Susceptibility of 310 nonfermentative gram-negative bacteria to aztreonam, carumonam, ciprofloxacin, ofloxacin and fleroxacin.

P C Appelbaum1, S K Spangler, T Tamarree.   

Abstract

The susceptibility of 310 mainly clinically isolated Gram-negative nonfermenters to aztreonam, carumonam, ciprofloxacin, ofloxacin and fleroxacin was determined by agar dilution. All 3 quinolones were very active, with MIC90 ranges (micrograms/ml) against all organisms ranging between 0.25 and 8 for ciprofloxacin, and 0.25 and 16.0 for ofloxacin and fleroxacin, respectively. Aztreonam and carumonam showed less activity than the quinolones on a weight-for-weight basis, with MIC90 values ranging from 4 to 32 for both drugs; only Pseudomonas aeruginosa and Acinetobacter calcoaceticus biotypes haemolyticus and alcaligenes were uniformly susceptible to both monobactams. The broad-spectrum activity of the 3 quinolones suggests potential use in therapy of infections caused by nonfermenters; monobactams should be reserved for infections caused by P. aeruginosa and possibly Acinetobacter spp.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3127127     DOI: 10.1159/000238546

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  13 in total

1.  Rapid differentiation of fermentative from nonfermentative gram-negative bacilli in positive blood cultures by an impedance method.

Authors:  T C Chang; A H Huang
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

Review 2.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

3.  Cross resistance to ciprofloxacin and other antimicrobial agents among clinical isolates of Acinetobacter calcoaceticus biovar anitratus.

Authors:  I Shalit; M Dan; R Gutman; A Gorea; S A Berger
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

4.  In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli.

Authors:  R J Fass; J Barnishan; M C Solomon; L W Ayers
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

5.  Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies.

Authors:  S Bajaksouzian; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

6.  Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.

Authors:  M A Visalli; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

Review 7.  Fleroxacin clinical pharmacokinetics.

Authors:  A E Stuck; D K Kim; F J Frey
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

8.  Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography.

Authors:  A J Fischman; E Livni; J W Babich; N M Alpert; A Bonab; S Chodosh; F McGovern; P Kamitsuka; Y Y Liu; R Cleeland; B L Prosser; J A Correia; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

9.  Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem.

Authors:  S K Spangler; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

10.  Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography.

Authors:  A J Fischman; E Livni; J Babich; N M Alpert; Y Y Liu; E Thom; R Cleeland; B L Prosser; J A Correia; H W Strauss
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.